CD22 and triple-negative breast carcinoma: CD22-mediated pathways have not been enriched in CRC prevention and treatment; however, CD22 has been used as an immunotherapy target in the treatment of tumors such as triple-negative breast cancer, liver cancer, and B-cell lymphoblastic lymphoma [57,58,59].